CNOT6L

Across TCGA pan-cancer cohorts, CNOT6L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CNOT6L data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CNOT6L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CNOT6L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where CNOT6L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.891	0.591	.002	21	view →
PDAC	DFS	Tertile	III,IV	0.624	0.174	.017	11	view →
LUAD	DFS	Quartile	All	0.998	0.833	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CNOT6L–CCRCC (DFS)

Open the CCRCC breakdown →